Is nonalcoholic fatty liver disease a predictor of treatment response in chronic hepatitis B?

We read with great interest the recent article by Tang et al. on the impact of status changes in nonalcoholic fatty liver disease (NAFLD) on the efficacy of antiviral therapy in HBeAg-positive patients with chronic hepatitis B (CHB). New-onset and sustained NAFLD failed to change the virological response (VR) but altered the biochemical response (BR) rate and fibrosis improvement compared to the sustained non-NAFLD group. These findings add new and compelling evidence to the paradoxical relationship between NAFLD and CHB. This article is protected by copyright. All rights reserved.